BBIO
Companies
NASDAQ
BridgeBio Pharma Inc.
Health Care
$42.18
+$14.74 (+53.72%)
Price Chart
Overview
About BBIO
we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
Market Cap
$5.1B
Volume
139.0M
Avg. Volume
137.0M
P/E Ratio
-11.016339
Dividend Yield
0.00%
Employees
444.0
Company Information
Latest News for BBIO
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
March 27, 2025
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
January 8, 2025
BridgeBio CEO Neil Kumar: Our heart disease drug staves off death and hospitalization
January 14, 2025
Trending stocks July 17, 2023: AT&T, BridgeBio Pharma, and PepsiCo
July 17, 2023
Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade
May 13, 2025
Risk & Correlation Analysis
Market Correlation
1.45
High Correlation
Volatility
High (0.64)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, BBIO shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$5.1B
Volume139.0M
P/E Ratio-11.02
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
April 30, 2025Related Securities
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025